薬物好酸球性副鼻腔炎4例に対するオマリズマブ(ゾレア)の使用経験

概要

論文の詳細を見る
Omalizumab (Xolair®) is an anti-IgE antibody drug that alleviates IgE-dependent allergy reactions via binding to serum IgE thereby reducing its level. In Japan, omalizumab has been prescribed for patients with severe allergic asthma since 2009. Because of the mechanism of action, omalizumab is expected to have positive effects on otorhinolaryngological symptoms, such as hay fever, allergic rhinitis, allergic sinusitis, and eosinophilic sinusitis. This study involved patients with eosinophilic sinusitis who were treated at the Department of Otorhinolaryngology, Japanese Red Cross Medical Center. Omalizumab was prescribed for 4 patients by the Department of Respiratory Medicine, and we therefore investigated the potential efficacy of the drug for the disease. Two of the 4 patients showed a tendency for improvement with omalizumab, while other two showed clear improvement of paranasal sinus pathology. These results would suggest that omalizumab could be a definitive treatment alternative for eosinophilic sinusitis, for which no curative therapeutic drugs or methods (besides the oral administration of steroids) are currently available. Detailed studies are needed to further evaluate the efficacy of omalizumab for eosinophilic sinusitis.